LRI Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

LRI Investments’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37	Buy	+1	New	+$37	﹤0.01%	1925

Other funds holding CRNX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

LAM

Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return

LRI Investments's CRNX Position: Q2 2026 in Review

LRI Investments opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1 share worth $37. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings.

51 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

LRI Investments held 1 share of Crinetics Pharmaceuticals worth $37 as of Q2 2026.
Crinetics Pharmaceuticals was a new LRI Investments position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1925 holding.
51 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.